| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 14, 2024 | Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases
Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trial
Management to host conference call ... |
| May 15, 2024 | Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | Announced private placement of up to $19.25M with healthcare funds and insiders
Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program
Acquired synergistic leptomeningeal metastases d... |
| Mar 5, 2024 | Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | |
| Aug 14, 2023 | Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights | ReSPECT clinical trial data continues to demonstrate promise for treatment of leptomeningeal metastases and recurrent glioblastoma
Received FDA approval to move into Phase 1/Part B of the ReSPECT-LM clinical trial
Management to host confere... |
| Nov 18, 2021 | Plus Therapeutics : Announces Positive Interim Data from ReSPECT-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting - Form 8-K | Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
Latest interim analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-lim... |
| Nov 18, 2021 | Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting | Latest interim analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-limiting toxicities
Mean and median overall survival in patients receiving absorbed dose greater than 100 Gy is 453.8 days and 330 days, respectivel... |
| Sep 30, 2021 | Plus Therapeutics : to Present ReSPECT™-GBM Clinical Trial Data at the 2021 SNO Annual Meeting | AUSTIN, Texas, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers... |